Dr Agarwals Eye Hospital Ltd
₹ 4,470
-0.63%
12 Jun
3:21 p.m.
About
Dr Agarwal's Eye Hospital Ltd is a leading chain of eye hospitals with predominant presence in Tamil Nadu.[1]
Key Points
- Market Cap ₹ 2,101 Cr.
- Current Price ₹ 4,470
- High / Low ₹ 7,300 / 3,016
- Stock P/E 38.4
- Book Value ₹ 446
- Dividend Yield 0.11 %
- ROCE 17.4 %
- ROE 29.8 %
- Face Value ₹ 10.0
Pros
- Company has delivered good profit growth of 32.3% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 33.3%
Cons
- Stock is trading at 10.0 times its book value
- Company might be capitalizing the interest cost
- Promoters have pledged 55.4% of their holding.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
113 | 118 | 137 | 149 | 153 | 170 | 176 | 140 | 201 | 268 | 319 | 397 | |
102 | 103 | 119 | 126 | 129 | 140 | 129 | 109 | 143 | 192 | 227 | 279 | |
Operating Profit | 11 | 15 | 18 | 23 | 24 | 30 | 47 | 31 | 59 | 76 | 92 | 118 |
OPM % | 9% | 13% | 13% | 15% | 16% | 18% | 27% | 22% | 29% | 28% | 29% | 30% |
3 | 0 | -5 | 1 | 2 | 2 | 3 | 1 | 1 | 2 | 5 | 5 | |
Interest | 4 | 4 | 5 | 4 | 3 | 4 | 9 | 7 | 7 | 8 | 8 | 13 |
Depreciation | 6 | 6 | 9 | 9 | 10 | 11 | 21 | 19 | 20 | 20 | 27 | 39 |
Profit before tax | 4 | 5 | -0 | 11 | 13 | 17 | 20 | 6 | 32 | 49 | 62 | 71 |
Tax % | 35% | -6% | -104% | 33% | 49% | 32% | 31% | 125% | 25% | 25% | 26% | 23% |
2 | 6 | 0 | 7 | 7 | 12 | 14 | -1 | 24 | 37 | 46 | 55 | |
EPS in Rs | 5.17 | 12.13 | 0.09 | 15.62 | 14.43 | 25.36 | 29.11 | -3.06 | 51.28 | 78.55 | 98.64 | 116.28 |
Dividend Payout % | 23% | 10% | 940% | 10% | 8% | 6% | 0% | 0% | 6% | 4% | 3% | 5% |
Compounded Sales Growth | |
---|---|
10 Years: | 13% |
5 Years: | 18% |
3 Years: | 25% |
TTM: | 24% |
Compounded Profit Growth | |
---|---|
10 Years: | 25% |
5 Years: | 32% |
3 Years: | 32% |
TTM: | 17% |
Stock Price CAGR | |
---|---|
10 Years: | 44% |
5 Years: | 77% |
3 Years: | 87% |
1 Year: | 40% |
Return on Equity | |
---|---|
10 Years: | 29% |
5 Years: | 30% |
3 Years: | 33% |
Last Year: | 30% |
Balance Sheet
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
Reserves | 14 | 19 | 19 | 25 | 30 | 41 | 51 | 50 | 73 | 109 | 152 | 205 |
28 | 27 | 31 | 23 | 18 | 24 | 60 | 68 | 193 | 232 | 268 | 333 | |
20 | 18 | 24 | 20 | 28 | 31 | 24 | 33 | 42 | 44 | 71 | 71 | |
Total Liabilities | 67 | 69 | 79 | 72 | 81 | 100 | 141 | 155 | 314 | 390 | 496 | 613 |
26 | 26 | 34 | 33 | 36 | 55 | 94 | 96 | 214 | 260 | 316 | 393 | |
CWIP | 0 | 0 | 1 | 1 | 3 | 0 | 0 | 0 | 26 | 62 | 97 | 128 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 13 |
41 | 43 | 44 | 38 | 42 | 45 | 47 | 60 | 73 | 67 | 83 | 80 | |
Total Assets | 67 | 69 | 79 | 72 | 81 | 100 | 141 | 155 | 314 | 390 | 496 | 613 |
Cash Flows
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
12 | 14 | 17 | 20 | 19 | 25 | 39 | 34 | 57 | 70 | 90 | 94 | |
-11 | -10 | -17 | -8 | -11 | -25 | -17 | -11 | -46 | -71 | -70 | -133 | |
-3 | -5 | -0 | -12 | -8 | 2 | -20 | -8 | -4 | 0 | -14 | 17 | |
Net Cash Flow | -2 | -1 | 0 | 0 | -0 | 2 | 2 | 15 | 7 | -1 | 6 | -22 |
Ratios
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 19 | 19 | 24 | 16 | 17 | 19 | 14 | 23 | 16 | 14 | 15 | 13 |
Inventory Days | 96 | 238 | 200 | 123 | 148 | 124 | 132 | 117 | 91 | 73 | 106 | 117 |
Days Payable | 137 | 360 | 371 | 277 | 353 | 292 | 224 | 401 | 410 | 327 | 345 | 263 |
Cash Conversion Cycle | -22 | -103 | -146 | -138 | -189 | -149 | -78 | -260 | -303 | -240 | -224 | -133 |
Working Capital Days | -23 | -5 | -23 | -18 | -28 | -11 | -6 | -20 | -29 | -24 | -40 | -14 |
ROCE % | 17% | 19% | 18% | 29% | 32% | 34% | 30% | 11% | 20% | 19% | 18% | 17% |
Documents
Announcements
- Corporate Action-Board approves Dividend 28 May
- Audited Results-31-03-2025 28 May
-
Board Meeting Outcome for Outcome Of The Board Meeting Dated May 28, 2025
28 May - Audited FY25 results with 60% total dividend; new auditors and MD reappointments approved.
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
23 May - Annual Secretarial Compliance Report for FY 2024-25 confirming regulatory adherence and resolved past non-compliances.
-
Board Meeting Intimation for Intimation Of Date Of Board Meeting
20 May - Board meeting on May 28 to approve FY25 audited results and consider final dividend.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Services Offered
The company's centers offer comprehensive services in the eye-care segment including cataract, glaucoma, laser correction, corner and refractive, retina, squint, etc. [1]